New indications approved by FDA for topical treatment of tick infestation in cats

Credit: lesichkadesign/Adobe Stock

Merck Animal Health has announced the new label indication for both fluralaner topical solution (Bravecto) and fluralaner and moxidectin topical solution (Bravecto Plus) for the treatment and control of Asian longhorned tick infestations in cats. Both products are the first US products labeled for both the treatment and control of Asian longhorned tick infestations.

The Asian longhorned tick is an invasive ixodid tick that is native to Japan, China, eastern Russia, and Korea. As of December 2021, the species has been located across more than a third of the United States, according to Merck. These ticks have the potential to quickly become an important tick species within pet populations and are known for carrying various viral, bacterial, and protozoal agents.

“We’re committed to protecting pets and pet owners alike from parasites that pose risks to both animal and human health. With the new indication [for these products], we can expand our ability to care for pets by offering an even broader range of parasite protection for cats,” said Dominique Sims, DVM, associate director, scientific affairs, Merck Animal Health, in an organizational release. “Veterinarians can now recommend a treatment option that provides more versatile protection than traditional flea and tick offerings, while giving cat owners peace of mind in knowing their pet is safe from infestations.”

Merck’s fluralaner topical solution for cats was previously indicated for treatment and prevention of flea infestations, treatment and control of black-legged ticks and Asian longhorned tick infestations for 12 weeks, and treatment and control of American dog tick infestations for 8 weeks.

Additionally, the fluralaner and moxidectin topical solution is also indicated for prevention of heartworm, treatment of infections with intestinal roundworm and hookworm, the ability to kill adult fleas, the treatment and prevention of flea infestations for 2 months, and treatment and control of black-legged tick infestations, American dog ticks, and Asian longhorned ticks for 2 months.

Reference

US FDA approves new indication for Merck Animal Health’s Bravecto (fluralaner topical solution) for cats and Bravecto Plus (fluralaner and moxidectin topical solution) for Cats. News release. September 6, 2022. Accessed September 8, 2022. https://www.merck-animal-health-usa.com/newsroom/fda-approves-new-indication-for-bravecto